25/04/2008
ReGen Therapeutics Plc (‘ReGen’ or the ‘Company’) announces that a full review of the extensive science behind its product ColostrininTM, has been today published online in the Journal of Alzheimer’s Disease.* This review states that when given orally ColostrininTM has been shown to have a stabilising effect on cognitive functions in improving the conditions of patients suffering from mild to moderate Alzheimer’s disease. This review concludes that, whilst further extensive studies are required to understand the mechanism by which ColostrininTM exerts its biological effects, ColostrininTM clearly has potential benefit in the prevention and treatment of neurodegenerative disorders.
ColostrininTM is marketed in North America and Australia under the brand name CogniSureTM as a nutritional supplement to ‘support healthy brain aging and cognition’ in humans** and is available through the professional channel of healthcare practitioners such as chiropractors and doctors. The product is expected to be launched in the European Union in 2008.
Summarising this publication Dr. Marian Kruzel*** a co-author of the report said:
‘This is a most comprehensive review regarding the potential utility of ColostrininTM in neurodegenerative disorders. It includes research into the novel mechanisms of action involved in neuroprotection and clearly presents Colostrinin’sTM biodiversity. This is the whole story of the potential of Colostrinin’sTM proactive function in age-associated mental capacity.’
Percy Lomax, Chairman and Chief Executive Officer of ReGen said:
‘This review paper demonstrates the hard scientific evidence concerning the activity of ColostrininTM. This amount of scientific evidence is unusual for a nutraceutical and should support the further development of our marketing platform. We would also stress that this paper adds weight to our view of the likely potential of our ColostrininTM derived peptide programme to produce a pharmaceutical product that will be used in the treatment of neurodegenerative diseases.’
For further information:
ReGen Therapeutics Plc
Percy Lomax
Tel No 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel No 020 7628 3396
David Scott/Nick Bealer
Alexander David Securities
Limited
Tel No 020 7448 9800
Adrian Duffield/Jon Davies
College Hill Associates
Tel No 020 7457 2020
* Istvan Boldogh and Marian L. Kruzel, Journal of Alzheimer’s Disease Vol. 13, Number 3, April 2008 p323-331, web address: www.j-alz.com/
** ColostrininTM for use as a human nutraceutical is licensed in North America and Australasia to Metagenics Inc. of San Clemente, California
(www.Metagenics.com). Discussions are ongoing with potential distributors in ther regions of the world.
*** Professor Marian L Kruzel PhD is ReGen’s Chief Scientific Consultant and is a faculty member of the Department of Integrative Biology and Pharmacology, The University of Texas, Medical School at Houston. He is an internationally recognized immunologist with an established interest and expertise in inflammation and age-related pathophysiology.
Notes for Editors:
Abstract of the Full Scientific Review:
Colostrum-derived proline-rich polypeptide, also known as ColostrininTM (CLN), has been shown to have a stabilizing effect on cognitive function in Alzheimer’s disease (AD) patients. This complex action of CLN could be related to prevention of amyloid-b peptide aggregation, as shown in in vitro studies, and its impact on delicate cassettes of signalling pathways common to cellular redox regulation, proliferation and differentiation. Studies on cultured cells showed that CLN modulates intracellular levels of reactive oxygen species (ROS), via regulating glutathione metabolism, activity of antioxidant enzymes and mitochondria function. Due to an improvement in senescence-associated mitochondrial dysfunction and a decrease in ROS generation, CLN decelerates the aging processes of both cultured cells and experimental animals. When given orally to mice, CLN increased the life-span and improved various motor and sensory activities. Although the molecular basis by which CLN exerts its diverse effects are still under investigation, the regulatory effect on the cellular redox state via maintenance of mitochondrial function and modification of ROS-induced cell signalling seem to be of great importance. In this article, we examine experimental data pertinent to the mechanism of action, including a review of CLN’s utility in the maintenance of physiological processes in which oxidative stress has an etiological role.
Keywords: Proline-rich polypeptide, immunomodulation, Alzheimer’s disease, age related disorders, amyloid-b, oxidative stress
About ReGen Therapeutics
ReGen Therapeutics PLC is a UK-based biopharmaceutical company engaged in the acquisition and development of therapies related to age related disorders including Alzheimer’s disease, Parkinson’s disease and other degenerative neurological disorders.
The Company is focused particularly on technologies that address large unmet medical need to maintain healthy brain ageing, as well as rehabilitation after traumatic brain injury. ReGen’s product pipeline comprises ColostrininTM a nutraceutical that is in full commercial production and had fbeen launched to the professional channel in the USA and Australia under the brand name CogniSureTM; a drug development programme based on ColostrininTM-derived peptides; and Phase II clinical trials on a novel formulation of Zolpidem for the treatment of brain trauma and reversal of dormancy.